Assessment of non-inferiority with meta-analysis: example of hypofractionated radiation therapy in breast and prostate cancer

Jane-Chloé Trone¹,², Edouard Ollier²,³, Céline Chapelle²,³, Patrick Mismetti²,³,⁴, Michel Cucherat⁵, Nicolas Magné⁴, Paul Jacques Zuffrey²,³,⁶ & Silvy Laporte²,³,⁴

The aim of this study was to propose a methodology for the assessment of non-inferiority with meta-analysis. Assessment of hypofractionated RT in prostate and breast cancers is used as an illustrative example. Non-inferiority assessment of an experimental treatment versus an active comparator should rely on two elements: (1) an estimation of experimental treatment’s effect versus the active comparator based on a meta-analysis of randomized controlled trials and (2) the value of an objective non-inferiority margin. This margin can be defined using the reported effect of active comparator and the percentage of the active comparator’s effect that is desired to be preserved. Non-inferiority can then be assessed by comparing the upper bound of the 95% confidence interval of experimental treatment’s effect to the value of the objective non-inferiority margin. Application to hypofractionated RT in breast cancer showed that hypofractionated whole breast irradiation (HWBI) appeared to be non-inferior to conventionally fractionated RT for local recurrence. This was not the case for accelerated partial breast irradiation (APBI). Concerning overall survival, non-inferiority could not be claimed for either HWBI or APBI. For prostate cancer, the lack of demonstrated significant superiority of conventional RT versus no RT precluded any conclusion regarding non-inferiority of hypofractionated RT.

Except for major therapeutics advances, demonstrate the superiority of a new treatment is a difficult task. Effectiveness is often comparable to the standard treatment but new treatment may provide other advantage. For example, in oncology, radiotherapy (RT) is an important component of cancer treatment, approximately 50% of all cancer patients receiving RT during their medical care¹. More than a third of men with localized prostate cancer are treated with external-beam RT while whole breast irradiation (WBI) remains the standard of care after breast-conserving surgery²,³. The duration of treatment of conventionally fractionated radiotherapy is long, 8–9 weeks for prostate cancer and 6–7 weeks for breast cancer. Hypofractionated RT (involving fewer treatments but a higher dose per treatment) has been developed to shorten RT. Hypofractionated RT, has several advantages including convenience for patients, increased treatment capacity based on the α/β model, and decreased cost⁴. Hypofractionated RT is not intended to provide a superiority efficacy than conventionally fractionated RT.

Traditional superiority trials are thus not well suited to evaluate efficacy of such treatments and non-inferiority trials have been proposed. The latter aim to demonstrate that a new treatment is not “inferior”, not “unacceptably worse” to the standard by a too large amount. That amount is called the non-inferiority margin. Demonstration
of a non-inferiority requires then a direct comparison between the new treatment and the standard treatment using the pre-defined non-inferiority margin as decision threshold. If non-inferiority of some treatments is clearly demonstrated by high powered and well-designed studies, in most cases available data are not sufficient, and a meta-analysis may be needed to summarize the available evidence. However, the assessment of non-inferiority from the literature faces two issues: (1) the choice of the non-inferiority margin and (2) the non-adapted design of most clinical studies.

First, the choice of the non-inferiority margins is a clinical judgment and may vary greatly between trials. Using a wide non-inferiority margin makes it easier to conclude to the non-inferiority but exposes to the risk to recommend a treatment that is (statistically) inferior to the standard treatment. A recent work has highlighted that non-inferiority margins used in clinical trials were very variable and often did not allow to preserve at least 50% of the active comparator's effect leading to potentially erroneous conclusions. Summarizing studies' conclusions obtained with variable non-inferiority margins represent a challenging issue. The calculation of an objectively predefined margin based on the active comparator effect could be a solution.

The second issue is that many studies have been carried out with an inappropriate design. Some of the studies may have been conducted as superiority trials. Even if these studies allow an estimation of the treatment effect, they cannot be individually used for the assessment of non-inferiority as no margin was defined a priori.

The aim of this study was to propose a methodology for the assessment of non-inferiority with meta-analysis. Assessment of hypofractionated RT in prostate and breast cancers was used to illustrate the method. In breast cancer, two modes of hypofractionated RT have been investigated: accelerated partial breast irradiation (APBI) techniques, consisting in a single irradiation limited to the zone in which the risk of recurrence is greatest, and hypofractionated whole breast irradiation (HWBI) where the radiation is given to the whole breast, but in larger daily doses using fewer treatments compared to conventional RT.

Materials and methods

Non-inferiority assessment with meta-analysis. To assess the non-inferiority of an experimental treatment versus an active comparator two quantities are needed: i) the value of the non-inferiority margin and ii) an estimation of experimental treatment's effect versus the active comparator. The procedure proposed in this work is divided in three steps:

1. The first step is the calculation of an objective non-inferiority margin. As recommended in the FDA guidelines, the non-inferiority margins could be defined on the basis of:

   a. the reported effect of active comparator versus control (HR_ACVsCtrl). If not directly available from the literature, it can be evaluated by performing a meta-analysis of randomized clinical trials. The endpoint used to evaluate this effect needs to be the same as the one used for the evaluation of the experimental treatment effect versus the active comparator in the first step of the procedure.

   b. The percentage of the active comparator's effect that is desired to be preserved.

   Based on these two quantities, it is possible to calculate an objective non-inferiority margin that allows to preserve a target percentage of the active comparator's effect. This calculus can be based either on the mean estimate of the active comparator's effect (HR_ACVsCtrl) or on the upper bound of the 95% confidence interval of the estimate of the active comparator's effect (UB_ACVsCtrl). The second proposal provides a more conservative margin. Non-inferiority margins can be calculated using the following formulae:

   \[
   \delta = \left( \frac{1}{HR_{ACVsCtrl}} \right)^{1-\alpha} \quad \text{and} \quad \delta^{\text{MAX}} = \left( \frac{1}{UB_{ACVsCtrl}} \right)^{1-\alpha}
   \]  

   with \(\alpha\) the target percentage of the active comparator's effect that is desired to be preserved.

   The second step is the estimation of the experimental treatment's effect versus the active comparator based on a meta-analysis of randomized control trials. The endpoint used for the meta-analysis has to be the same as the one used for the evaluation of active comparator's effect in the first step. In this first step, all the randomized trial that have evaluated the experimental treatment versus the active comparator need to be included. Studies with an inappropriate design, such as superiority trials, should be considered to improve the statistical power of the comparison.

   Finally, the third step corresponds to the assessment of non-inferiority. It is performed by comparing the upper bound of the 95% confidence interval of the experimental treatment's effect calculated in step 1 with the objective non-inferiority margins calculated in step 2. The procedure is represented schematically in Fig. 1.

Application to hypofractionated RT in breast and prostate cancer. For each cancer location and clinical endpoint, the objectives margins were calculated in order to preserve at least 50% of the reported effect of conventionally fractionated RT. We performed a literature search to identify studies or meta-analysis that estimated the effect of conventional fractionated RT for each cancer location.

Assessment of hypofractionated RT effect. Literature search. We performed a systematic review of published phase 2 and phase 3 randomized clinical trials comparing conventional RT with hypofractionated RT, for prostate or breast cancer. Trials using adjuvant treatments, such as chemotherapy or hormonal therapy, were eligible for inclusion if the adjuvant treatment was used in both the experimental and active control groups.
An independent review of citations in the Medline database from May 1990 (first randomized clinical trial evaluating hypofractionated RT) to July 2019 was conducted. The keywords employed in our search included “clinical trial, hypofractionation, hypofractionated, accelerated radiation therapy, stereotactic and radiosurgery”. The search was not restricted to articles published in English. To verify the completeness of our search, we compared our findings with those of previously published meta-analyses on the same subject. We reviewed every publication identified, and in the event of duplicate publications, the most recent report of the selected clinical trial was included in the meta-analysis.

Data collection and analysis—study selection. Two of the authors (JCT and EO) independently evaluated studies for possible inclusion, any disagreements being resolved by discussion.

Data extraction and management. Data were independently extracted by two of the authors (JCT and EO). In the event of discrepancies between the reviewers, a consensus was reached by discussion.

For each clinical trial, we extracted details of the study characteristics (names of authors; year of publication; number of patients randomized to each treatment group); study design (double-blind vs. open-label); methodological qualities according to the Cochrane tool, taking into account random sequence generation, concealment of the allocation sequence, blinding of participants and personnel, blinding of outcome assessment, incomplete outcome data and selective reporting (Supplementary Table S1); patient characteristics (mean age, gender; disease stage, cancer location); characteristics of the radiotherapy regimens evaluated (volume of tissue irradiated, total dose, dose per fraction, methods of radiation); primary outcomes (overall survival (OS), local recurrence in the ipsilateral breast, or biochemical failure (BCF) in prostate cancer), toxicity (including acute and late adverse events in each group) and cosmetic outcome for breast cancer. In the event of missing data, we completed data extraction by reference to previously published meta-analyses.

Endpoints. The endpoints of our meta-analysis were local recurrence and OS for breast cancer, and BCF and OS for prostate cancer. The hazard ratio (HR) was used to summarize the results for each endpoint. In each individual trial, the HRs for hypofractionated RT compared to conventional fractionated RT and their 95% confidence interval (95% CI) were either extracted from the corresponding publication or derived from the number of deaths in each treatment group and the log-rank P value reported in the publication. When the log-rank P value was missing, HRs were derived from the survival curves or estimated according to the corresponding risk ratio (RR).

Meta-analyses. We used a fixed-effects model based on the logarithm of the HR weighted by the inverse of the variance to combine the results of individual trials. For each meta-analysis, statistical heterogeneity between the studies was explored using Cochran’s Q statistic, study consistency being quantified by means of the I² statistic. In the event of significant heterogeneity (P value < 0.10) with no clear explanation, a random-effect model was used for data analysis. To avoid divide-by-zero errors, we used a 0.5 zero-cell correction.

The results of the meta-analyses are presented graphically, including the effect size expressed as the HR with the corresponding 95% CI. An HR equal to 1 indicates no difference between the treatments, an HR less than 1 indicating that hypofractionated RT is better and an HR greater than 1 indicating that the control (conventionally fractionated RT) is better. We explored the publication bias of the studies included in the final analysis using Begg’s funnel plot and Egger’s test (Supplementary Fig. S2).

All statistical analyses were performed using R statistical software, version 3.3.1 with the meta packages (version 4.7).
Assessment of historical NI margin. We also extracted the non-inferiority margins used in the literature for each cancer location. Based on Eq. (1), we calculated the percentage $\alpha$ of the effect of conventionally fractionated RT preserved with each of the published non-inferiority margins. This calculation was done using the following formula:

$$\alpha = \frac{\log(\delta) + \log(HR_{ACVsCtrl})}{\log(HR_{ACVsCtrl})}$$

where $\delta$ corresponds respectively to the non-inferiority margins used in the study of interest and $HR_{ACVsCtrl}$ to the mean estimate of the active comparator’s effect, the conventionally fractionated RT in this example.

Results
Determination of the non-inferiority margins. Breast cancer. A previous published meta-analysis of 17 randomized trials in breast cancer explored the efficacy of RT versus no RT\textsuperscript{20}. The risk ratio (RR) for local recurrence was 0.50 (95% CI 0.46–0.55) and the RR for OS was 0.92 (95% CI 0.86–0.99) in favor of RT.

To calculate the non-inferiority margins for local recurrence corresponding to 50% of the effect of conventionally fractionated RT, we considered both the value of $HR_{CRTVsCtrl}$ (0.50) and the value of the upper bound of its 95% CI $UB_{CRTVsCtrl}$ (0.55).

$$\delta_{50\%} = \left( \frac{1}{0.50} \right)^{1-0.5} = 1.41$$

and

$$\delta_{\text{MAX}50\%} = \left( \frac{1}{0.55} \right)^{1-0.5} = 1.35$$

We also determined objective non-inferiority margins for OS: $\delta_{50\%}$= 1.04 and $\delta_{\text{MAX}50\%}$ = 1.01 (Table 1).

Prostate cancer. With regard to historical trials evaluating the efficacy of conventional fractionated RT in prostate cancer, our literature search identified only one study, which compared conventional fractionated RT with surveillance\textsuperscript{21}. As regards OS, the hazard-ratio was non-significant (0.51 [95% CI, 0.15–1.69]). No data concerning BCF were reported. The upper limit of the 95% CI for OS was above 1 (1.69) and did not permit the calculation of $\delta_{50\%}$.\n
Experimental treatment’s effect versus active comparator. Identification and description of relevant studies. Our search procedure identified 2,281 potentially relevant clinical trials. After a review of the publications, 32 trials were considered eligible for inclusion in the meta-analysis, yielding a total of 19,623 patients and 35 direct comparisons (3 studies having multiple arms) (Fig. 2).

The baseline characteristics of the studies included are presented in supplementary (Table S3). Twenty studies concerned breast cancer and 12 studies concerned prostate cancer\textsuperscript{12–33}. Among the 7 APBI\textsuperscript{34–40} studies, 6 were designed as non-inferiority trials and one did not specify the design of the trial. In the 13 HWBI\textsuperscript{11–39}, 2 were designed as non-inferiority trials, 2 as superiority trials and in 9 studies did mention the design of the trial. In the 12 prostate cancer studies, 5 were designed as non-inferiority trials, 4 as superiority trials and 3 did not report the design of the trial. Among the 13 studies designed as non-inferiority trials, the non-inferiority margin was specified in 9 cases (69%). The primary endpoint was toxicity in 15 trials, local recurrence in 10 trials, and BCF-free survival in 5 studies.

Hypofractionated whole breast irradiation. Local recurrences and OS were documented in 9 and 5 of the 13 HWBI studies respectively.

Figure 3 represents for each clinical endpoint the estimates of hypofractionation efficacy obtain with meta-analysis compared to the calculated objective margins, most permissive and most conservative published margin.
For local recurrence, whatever the margin considered, hypofractionation seemed to be non-inferior to conventional-fractionated group (HR 1.01, 95% CI 0.85–1.20).

Objectively calculated non-inferiority margins were very close to 1 (1.01 et 1.04) and did not allow any conclusion to be drawn regarding the non-inferiority of hypofractionated RT (HR 0.97, 95% CI 0.81–1.16). Forest plots of the meta-analysis are displayed in the supplementary data (Supplementary Fig. S4).

Accelerated partial breast irradiation. Local recurrences were documented in 6 of the 7 articles identified concerning APBI and OS in 5 of these studies.

Whatever the margins considered, we could not demonstrate the non-inferiority of hypofractionated RT as regards to recurrence (HR 1.91, 95% CI 0.90–4.06) (Fig. 3). With respect to OS, as in the case of HWBI, it was not possible to draw any conclusion as the objectively calculated margins were close to 1 (HR 0.86, 95% CI 0.65–1.16). Forest plots of the meta-analysis are displayed in the supplementary data (Supplementary Fig. S5).

Prostate cancer. BCF and OS were documented in 10 of the 12 prostate cancer studies. Published margins were only available for BCF.

Non-inferiority of hypofractionation on BCF is only suggested on the basis of the reported margin (HR 0.94, 95% CI 0.83–1.07) (Fig. 3). For OS, no conclusion could be drawn in the absence of any published or calculable margin (HR 0.90, 95% CI 0.80–1.02). Forest plots of the meta-analysis are displayed in the supplementary data (Supplementary Fig. S6).

Assessment of historical NI margin. We extracted from the studies included in the meta-analysis the non-inferiority margins used within each non-inferiority trial (See Table 1 and Supplementary Table S3) and then calculated the percentage of the effect of conventionally fractionated RT preserved with each of the published non-inferiority margins using Eq. (2).
With regard to HWBI and APBI, Fig. 4 represents the relationship between the value of the non-inferiority margin and the percentage of preserved effect of conventionally fractionated RT for local recurrence. Only one study used a non-inferiority margin corresponding to an effect close to 50% of the conventionally fractionated RT’s effect \(^{38}\). Other studies only allowed to retain 25% of the effect of conventional RT \(^{34,37,42}\). One study have a negative percentage of preserved effect and so could lead to accept treatment with a deleterious effect \(^{39}\).
For OS, no published margin was available. For APBI, the most conservative margin used in the literature was close to objective margin (1.42 vs 1.41).

Concerning prostate cancer this calculation was impossible as no randomized study in prostate cancer demonstrated a significant superiority of conventional RT versus no RT.

**Discussion**

The present work proposed to assess the non-inferiority of an experimental treatment compared to an active comparator using a meta-analytical approach. The proposed method is based on two steps procedure. The first step corresponds to an estimation of experimental treatment’s effect versus the active comparator while the second step corresponds to the calculation of an objective non-inferiority margin. The method is illustrated using the comparison between hypofractionated RT and conventional RT for breast and prostate cancer. These two examples highlight the different issues that can occur when performing such analysis.

Controlled trials with a non-inferiority design have the advantage of potentially providing proof that the difference between a novel treatment and an active control treatment is sufficiently small to support authorization of the proposed new treatment. Non-inferiority trials are particularly appropriate in the case of hypofractionated RT, a mode of treatment with clear practical and financial advantages, to verify the absence of loss of efficacy in comparison to conventional RT. However, there are rules concerning appropriate use of the non-inferiority study design to provide evidence of comparative efficacy. First, the effectiveness of the standard treatment needs to be demonstrated. Second, the non-inferiority margins employed should be pre-specified and preferably justified on clinical grounds.

An excellent demonstration of the non-inferiority of HWBI was obtained for local recurrence. First, conventional RT resulted in a reduced risk of local recurrence in comparison to no treatment. Second, irrespective of the non-inferiority margin used, HWBI appeared to be non-inferior to conventional RT. With regard to OS, no conclusion could be drawn because the objectively calculated margins were very close to 1.

Concerning APBI, we could not conclude that hypofractionated APBI was non-inferior to conventional RT in the light of the prespecified margins and their 95% confidence intervals. In prostate cancer, we found no evidence proving the efficacy of conventional RT compared to no RT. This lack of data makes it impossible to define an objective non-inferiority margin.

Concerning the prespecified margins reported, most of the published trials included in our meta-analysis used a non-inferiority margin that was too wide to ensure preservation of a sufficient proportion (50%) of the active comparator’s effectiveness, probably in order to more easily conclude non-inferiority of hypofractionated RT. Determination of the margin in a non-inferiority trial should be based on both statistical reasoning and clinical judgement, but most of the studies offered no justification for their prespecified margins. For example, the use of conventional RT as the active comparator in studies concerning prostate cancer, when this treatment has not been shown to have significant efficacy in previous randomized trials, complicates the definition of a non-inferiority margin. At the same time, the use of a placebo as the comparator does not appear to be ethical in cancer patients. Despite the increased interest in methodology and the definition of non-inferiority margins during recent years, more efforts are required to avoid erroneous declarations of non-inferiority. A consensus on the preferred method for defining non-inferiority margins is needed.

Our study had several limitations. First, the relevance of intention-to-treat analysis versus per-protocol analysis was not addressed. Per-protocol analysis, by excluding patients who failed to complete the full course of treatment, is more likely to reflect differences between the two treatments compared. Second, the objective of the studies included in the meta-analysis (non-inferiority versus superiority) was in general not clearly defined and so no non-inferiority margins were specified. Finally, the cutoff used to define adequate preservation of the active comparator’s treatment effect (50%) was subjective and in some settings may be clinically insufficient.

In conclusion, we found that hypofractionated RT seemed to be non-inferior to conventional RT only in the context of HWBI and with respect to the endpoint of local recurrence. APBI was not as effective as WBI following our methodology. No conclusion could be drawn for prostate cancer, as the use of an active comparator (conventional RT) in this context did not significantly improve overall survival and the efficacy of conventional RT with regard to BCF has not been evaluated in any clinical study.

It is meaningless to declare non-inferiority of a novel intervention in the absence of any prior evidence of the effectiveness the active comparator. It would be of interest to compare the use of hypofractionated RT with active monitoring in prostate cancer.

**Data availability**

The datasets analyzed during the current study are available from the corresponding author on request.

Received: 31 January 2020; Accepted: 20 August 2020

**Published online:** 22 September 2020

**References**

1. Baskar, R., Lee, K. A., Yeo, R., & Yeoh, K.-W. Cancer and radiation therapy: current advances and future directions. *Int. J. Med. Sci.* **9,** 193–199 (2012).
2. Mahmood, U. *et al.* Current clinical presentation and treatment of localized prostate cancer in the United States. *J. Urol.* **192,** 1650–1656 (2014).
3. Parker, C., Gillessen, S., Heidenreich, A., & A. Cancer of the prostate: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. *Ann. Oncol.* **26**(Suppl 5), v69–v77 (2015).
4. Senkus, E. *et al.* Primary breast cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. *Ann. Oncol.* **26**(Suppl 5), v83–v30 (2015).
5. Senkus, E. *et al.* Breast cancer (metastatic): ESMO clinical practice guidelines for diagnosis, treatment and follow-up. *Ann. Oncol.* **26**(Suppl 5), v32–v62 (2015).
6. Senkus, E. *et al.* Primary breast cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. *Ann. Oncol.* **26**(Suppl 5), v83–v30 (2015).
7. Senkus, E. *et al.* Breast cancer (metastatic): ESMO clinical practice guidelines for diagnosis, treatment and follow-up. *Ann. Oncol.* **26**(Suppl 5), v32–v62 (2015).
8. Senkus, E. *et al.* Early breast cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. *Ann. Oncol.* **26**(Suppl 5), v1–v76 (2015).
9. Senkus, E. *et al.* Early breast cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. *Ann. Oncol.* **26**(Suppl 5), v1–v76 (2015).
10. Senkus, E. *et al.* Breast cancer (metastatic): ESMO clinical practice guidelines for diagnosis, treatment and follow-up. *Ann. Oncol.* **26**(Suppl 5), v83–v30 (2015).
11. Senkus, E. *et al.* Early breast cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. *Ann. Oncol.* **26**(Suppl 5), v1–v76 (2015).
12. Senkus, E. *et al.* Breast cancer (metastatic): ESMO clinical practice guidelines for diagnosis, treatment and follow-up. *Ann. Oncol.* **26**(Suppl 5), v32–v62 (2015).
13. Senkus, E. *et al.* Early breast cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. *Ann. Oncol.* **26**(Suppl 5), v1–v76 (2015).
14. Senkus, E. *et al.* Breast cancer (metastatic): ESMO clinical practice guidelines for diagnosis, treatment and follow-up. *Ann. Oncol.* **26**(Suppl 5), v32–v62 (2015).
15. Senkus, E. *et al.* Early breast cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. *Ann. Oncol.* **26**(Suppl 5), v1–v76 (2015).
16. Senkus, E. *et al.* Breast cancer (metastatic): ESMO clinical practice guidelines for diagnosis, treatment and follow-up. *Ann. Oncol.* **26**(Suppl 5), v32–v62 (2015).
17. Senkus, E. *et al.* Early breast cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. *Ann. Oncol.* **26**(Suppl 5), v1–v76 (2015).
18. Senkus, E. *et al.* Breast cancer (metastatic): ESMO clinical practice guidelines for diagnosis, treatment and follow-up. *Ann. Oncol.* **26**(Suppl 5), v32–v62 (2015).
19. Senkus, E. *et al.* Early breast cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. *Ann. Oncol.* **26**(Suppl 5), v1–v76 (2015).
20. Senkus, E. *et al.* Breast cancer (metastatic): ESMO clinical practice guidelines for diagnosis, treatm
5. Brenner, D. J. Toward optimal external-beam fractionation for prostate cancer. *Int. J. Radiat. Oncol. Biol. Phys.* **48**, 315–316 (2000).

6. Tsui, M., Rehal, S., Jairath, V. & Khan, R. C. Most noninferiority trials were not designed to preserve active comparator treatment effects. *J. Clin. Epidemiol.* **110**, 82–89 (2019).

7. U.S. Department of Health and Human Services Food and Drug Administration. *Non-Inferiority Clinical Trials to Establish Effectiveness Guidance for Industry*. 56 (2016).

8. Kaul, S. & Diamond, G. A. Good enough: a primer on the analysis and interpretation of noninferiority trials. *Ann. Intern. Med.* **145**, 62–69 (2006).

9. Higgins, J. P. T. *Meta-Analysis of Observational Studies in Epidemiology*. Oxford: Blackwell Science (2011).

10. Zhu, Z. et al. Efficacy and toxicity of external-beam radiotherapy for localised prostate cancer: a network meta-analysis. *Br. J. Cancer* **110**, 2396–2404 (2014).

11. Valle, L. F. et al. Hypofractionated whole breast radiotherapy in breast conservation for early-stage breast cancer: a systematic review and meta-analysis of randomized trials. *Breast Cancer Res. Treat.* **169**, 409–417 (2017).

12. Hickey, B. E., Lehman, M., Francis, D. P. & See, A. M. Partial breast irradiation for early breast cancer. *Cochrane Database Syst Rev* **7**, CD007077 (2016).

13. Xiong, T. et al. Comparative efficacy and safety of treatments for localised prostate cancer: an application of network meta-analysis. *BMJ Open* **4**, e004285 (2014).

14. Parmar, M. K. B., Torri, V. & Stewart, L. Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. *Stat. Med.* **17**, 2815–2834 (1998).

15. Higgins, J. P. T., Thompson, S. G., Deeks, J. J. & Altman, D. G. Measuring inconsistency in meta-analyses. *Stat. Med.* **23**, 731–754 (2004).

16. Bradburn, M. J., Deeks, J. J., Berlin, J. A. & Localio, A. R. Much ado about nothing: a comparison of the performance of meta-analytical methods with rare events. *Stat. Med.* **26**, 53–77 (2007).

17. Begg, C. B. & Mazumdar, M. Operating characteristics of a rank correlation test for publication bias. *Biometrics* **50**, 1088–1101 (1994).

18. Egger, M., Davey Smith, G., Schneider, M. & Minder, C. Bias in meta-analysis detected by a simple, graphical test. *BMJ* **315**, 629–634 (1997).

19. Early Breast Cancer Trials’ Collaborative Group (EBCTCG). Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10 801 women in 17 randomised trials. *Lancet* **378**, 1707–1716 (2011).

20. Hamdy, F. C. et al. 10-year outcomes after monitoring, surgery, or radiotherapy for localized prostate cancer. *N. Engl. J. Med.* **375**, 1415–1424 (2016).

21. Catton, C. N. et al. Randomized trial of a hypofractionated radiation regimen for the treatment of localized prostate cancer. *J. Clin. Oncol.* **35**, 1884–1890 (2017).

22. Dearnaley, D. et al. Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: 5-year outcomes of the randomised, non-inferiority, phase 3 CHHiP trial. *Lancet Oncol.* **17**, 1047–1060 (2016).

23. Lee, W. R. et al. Randomized phase III noninferiority study comparing two radiotherapy fractionation schedules in patients with low-risk prostate cancer. *J. Clin. Oncol.* **34**, 2325–2332 (2016).

24. Lukka, H. et al. Randomized trial comparing two fractionation schedules for patients with localized prostate cancer. *J. Clin. Oncol.* **23**, 6132–6138 (2005).

25. Arcangeli, G. et al. Moderate hypofractionation in high-risk, organ-confined prostate cancer: final results of a phase III Randomized trial. *J. Clin. Oncol.* **35**, 1891–1897 (2017).

26. Yeoh, E. E. et al. Hypofractionated versus conventionally fractionated radiotherapy for prostate carcinoma: final results of phase III randomized trial. *Int. J. Radiat. Oncol. Biol. Phys.* **81**, 1271–1278 (2011).

27. Pollack, A. et al. Randomized trial of hypofractionated external-beam radiotherapy for prostate cancer. *J. Clin. Oncol.* **31**, 3860–3868 (2013).

28. Incrocci, L. et al. Hypofractionated versus conventionally fractionated radiotherapy for patients with localized prostate cancer (HYPRO): final efficacy results from a randomised, multicentre, open-label, phase 3 trial. *Lancet Oncol.* **17**, 1061–1066 (2016).

29. Hoffman, K. E. et al. Risk of late toxicity to normal tissues in men receiving dose-escalated hypofractionated intensity modulated prostate radiation therapy: results from a randomised trial. *Int. J. Radiat. Oncol. Biol. Phys.* **88**, 1074–1084 (2014).

30. Norkus, D., Miller, A., Pleskienke, A., Janulionis, E. & Valuckas, K. P. A randomized trial comparing hypofractionated and conventionally fractionated three-dimensional conformal external-beam radiotherapy for localized prostate adenocarcinoma: a report on the first-year biochemical response. *Medicina (Kaunas)* **45**, 469–475 (2009).

31. Marzi, S. et al. Modeling of alpha/beta for late rectal toxicity (beta) for patients from a randomised phase II study: conventional versus hypofractionated scheme for localized prostate cancer. *J. Exp. Clin. Cancer Res.* **28**, 117 (2009).

32. Hoffman, K. E. et al. Randomized trial of hypofractionated, dose-escalated, intensity-modulated radiation therapy (IMRT) versus conventionally fractionated IMRT for localized prostate cancer. *J. Clin. Oncol.* **36**, 2943–2949 (2018).

33. Livi, L. et al. Accelerated partial breast irradiation using intensity-modulated radiotherapy versus whole breast irradiation: 5-year survival analysis of a phase 3 randomised controlled trial. *Eur. J. Cancer* **51**, 451–463 (2015).

34. Polgár, C., Fodor, I., Major, T., Sulyok, Z. & Kásler, M. Breast-conserving therapy with partial or whole breast irradiation: ten-year results of the Budapest randomized trial. *Radiother. Oncol.* **108**, 197–202 (2013).

35. Rodríguez, N. et al. Five-year outcomes, cosmesis, and toxicity with 3-dimensional conformal external beam radiation therapy to deliver accelerated partial breast irradiation. *Int. J. Radiat. Oncol. Biol. Phys.* **87**, 1051–1057 (2013).

36. Strnad, V. et al. 5-year results of accelerated partial breast irradiation using self-intersitial multicatheter brachytherapy versus whole-breast irradiation with boost after breast-conserving surgery for low-risk invasive and in-situ carcinoma of the female breast: a randomised, phase 3, non-inferiority trial. *Lancet Oncol.* **17**, 229–236 (2016).

37. Vaidya, J. S. et al. Targeted intraoperative radiotherapy versus whole breast radiotherapy for breast cancer (TARGET-A trial): an international, prospective, randomised, non-inferiority phase 3 trial. *Lancet Oncol.* **17**, 91–102 (2010).

38. Veronesi, U. et al. Intraoperative radiotherapy versus external radiotherapy for early breast cancer (ELIoT): a randomised controlled equivalence trial. *Lancet Oncol.* **14**, 1269–1277 (2013).

39. Struikmans, H. et al. Single dose IOERT versus whole breast irradiation: Cosmetic results in breast-conserving therapy. *Strahlenther. Onkol.* **192**, 705–713 (2016).

40. Spornen, D. et al. A randomised controlled trial to evaluate both the role and the optimal fractionation of radiotherapy in the conservative management of early breast cancer. *Clin. Oncol. (R. Coll. Radiol.)* **24**, 697–706 (2012).

41. Whelan, T. J. et al. Long-term results of hypofractionated radiotherapy for breast cancer. *N. Engl. J. Med.* **362**, 513–520 (2010).

42. Owen, J. R. et al. Effect of radiotherapy fraction size on tumour control in patients with early-stage breast cancer after local tumour excision: long-term results of a randomised trial. *Lancet Oncol.* **7**, 467–471 (2006).

43. Fragkandrea, I. et al. Radiation induced pneumonitis following whole breast radiotherapy treatment in early breast cancer patients treated with breast conserving surgery: a single institution study. *Hydrogen, sharks and radiotherapy*. *Hypokreis* **23**, 233–238 (2007).

44. Li, S. et al. Interim analysis of 354 breast cancer patients randomly treated With hyperfractionated or conventional fractionated radiotherapy after breast-conserving surgery. *Int. J. Radiat. Oncol. Biol. Phys.* **90**, S256 (2014).
46. Saha, S., Dastidar, A. G., Gangopadhyay, A. & Ghora, S. Evaluation of hypofractionated adjuvant radiotherapy for early breast cancer: a prospective randomized study. Int. J. Radiat. Oncol. Biology Phys. 75, S76 (2009).
47. Patni, N., Jain, M., Patni, S. & Bapna, A. A comparison of acute and chronic toxicity profile between conventional and hypofractionated whole breast irradiation in patients undergoing breast conserving surgery. Int. J. Radiat. Oncol. Biol. Phys. 84, S232 (2012).
48. Haislunod, B., Bang, T., Ellegaard, M. B. & Offeresen, B. PO-0934 acute morbidity in patients with early breast cancer in adjuvant radiotherapy in the D8CG hypo and D8CG PBI protocols. Radiother. Oncol. 103, S375–S376 (2012).
49. FAST Trialists group et al. First results of the randomised UK FAST Trial of radiotherapy hypofractionation for treatment of early breast cancer (CRUK/E04/015). Radiother. Oncol. 100, 93–100 (2011).
50. Van Parijs, H. et al. Short course radiotherapy with simultaneous integrated boost for stage I-II breast cancer, early toxicities of a randomized clinical trial. Radiother. Oncol. 7, 80 (2012).
51. Taher, A. N., El-Baradie, M. M., Essa, H., Zaki, O. & Ezzat, S. Hypofractionation versus conventional fractionation radiotherapy after conservative treatment of breast cancer: early skin reactions and cosmetic results. J. Egypt. Natl. Cancer Inst. 16, 178–187 (2004).
52. Baillet, F. et al. The use of a specific hypofractionated radiation therapy regimen versus classical fractionation in the treatment of breast cancer: a randomized study of 230 patients. Int. J. Radiat. Oncol. Biol. Phys. 19, 1131–1133 (1990).
53. Barsoum, M. S. et al. Prospective randomized trial comparing postoperative adjuvant concurrent versus sequential hormonal and different radiation fractionation schedule in breast cancer patients. JCO 28, 344–344 (2010).
54. European Medicines Agency. Committee for medicinal products for human use (CHMP) guideline on the choice of the non-inferiority margin. Statist. Med. 25, 1628–1638 (2006).
55. Piaggio, G. et al. Reporting of noninferiority and equivalence randomized trials: extension of the CONSORT 2010 statement. JAMA 308, 2594–2604 (2012).
56. Rehal, S., Morris, T. P., Fielding, K., Carpenter, J. R. & Phillips, P. P. J. Non-inferiority trials: are they inferior? A systematic review of reporting in major medical journals. BMJ Open 6, e012594 (2016).

Acknowledgements
EO thanks the Nuovo Soldati Fellowship Fund for its support.

Author contributions
J.C.T. designed the study, analyzed the data, drafted the manuscript and gave final approval of the version to be published. E.O. designed the study, analyzed the data, wrote the manuscript and gave final approval of the version to be published. C.C. analyzed the data and gave final approval of the version to be published. P.M. wrote the manuscript and gave final approval of the version to be published. M.C. designed the study, analyzed the data, and gave final approval of the version to be published. N.M. designed the study and gave final approval of the version to be published. P.J.Z. wrote the manuscript and gave final approval of the version to be published. S.L. designed the study, wrote the manuscript and gave final approval of the version to be published.

Competing interests
The authors declare no competing interests.

Additional information
Supplementary information is available for this paper at https://doi.org/10.1038/s41598-020-72088-2.

Correspondence and requests for materials should be addressed to J.-C.T.

Reprints and permissions information is available at www.nature.com/reprints.

Publisher's note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2020